Editoria e Media
Visiongain Report: The Gene Therapy Market is Projected to Grow at a CAGR of 32% in the First Half of the Forecast Period
LONDON , April 17, 2020 /PRNewswire/ -- The gene therapy market is projected to grow at a CAGR of 32% in the first half of the forecast period. In 2019, the cancer treatment submarket accounted for 55.8% of the gene therapy drug market. Visiongain estimated that gene therapy for rare diseases will be the driver for market growth in the first half of the forecast period.
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand-new you will receive – all unavailable elsewhere.
The 215-page Visiongain report provides clear detailed insight into the gene therapy market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
from
• This report in the market and gives
• Provides of the for the period 2020-2030:
• Profiles that will be important in the development of the gene therapy market. For each company, developments and outlooks are discussed and companies covered in this chapter include:
• UniQure
• Biogen
• Bluebird Bio
• Spark Therapeutics
• Applied Genetics Technologies Corporation
• Oxford Biomedica
• GenSight Biologics
• & Other Companies
• Assesses the outlook for the for 2019 and discusses technological progress and potential. Profiles appear for gene therapy drug candidates, with
• Collategene (AMG0001, AnGes MG/Vical)
• BC-819 (BioCancell)
• BC-821 – BioCancell
• SPK-CHM – Spark Therapeutics
• SPK-FIX – Spark Therapeutics/Pfizer
• SPK-TPP1- Spark Therapeutics
• Lenti-D (Bluebird Bio)
• LentiGlobin (Bluebird Bio)
• VM202-DPN – ViroMed
• Provides qualitative analysis of trends that will affect the gene therapies market, from the perspective of pharmaceutical companies, during the period 2020 to 2030. is provided and an given
• Our study discusses including these:
• Translation of research into marketable products modifying human DNA – gene transfer for therapeutic use, altering the nuclear genome
• Genomic editing technology and other supporting components
• Collaborations to develop and launch gene-based products – acquisitions and licensing deals
• Supporting technologies for human genetic modification, gene replacement and targeted drug delivery
• Gene therapies for ophthalmologic diseases – next-generation medicines
• Regulations in the United States , the European Union and
Japan – overcoming technological and medical challenges to pass clinical trials.
4DMT (4D Molecular Therapeutics)
Abeona
AGTC (Applied Genetics Technologies Corporation)
AMT (Amsterdam Molecular Therapeutics)
AnGes MG
Asklepios BioPharma
AstraZeneca
Audentes Therapeutics
Avalanche Biotech
Bayer Healthcare
Beijing Northland Biotech Co
Benda Pharmaceutical
Benitec Biopharma
BioCancell
Biogen
Biogen Idec
Bluebird Bio
BMS (Bristol-Myers Squibb)
Broad Institute/Whitehead Institute
Celgene
Cell Therapy Catapult
Cellectis
Chiesi Farmaceutici
Clearside Biomedical
Convergence Pharmaceuticals
Daiichi Sankyo
Dimension Therapeutics
Editas Medicine
Fondazione Telethon
Francis Crick Institute
Genable Technologies Ltd
Genethon
GenSight Biologics
GenVec
Google
GSK (GlaxoSmithKline)
Henry Ford Health System
HSCI (Human Stem Cells Institute)
HSR-TIGET (San Raffaele Telethon Institute for Gene Therapy),
ImaginAb
Immune Design Corp
InoCard
Inovio
Intellia Therapeutics
Invetech
Kite Pharma
Kolon Group
Kolon Life Science
Lysogene
Mitsubishi Tanabe Pharma Corporation
Neuralgene
NightstaRx
Northwestern Memorial Hospital
Novartis
OXB (Oxford Biomedica)
Pfizer
PNP Therapeutics
Precision Genome Engineering Inc aka Pregenen
ProNai
Protek Group
Raffaele Hospital
REGENX Biosciences
Renova Therapeutics
Roche
Roszdravnadzor
Sangamo Biosciences
Sanofi
Sarepta Therapeutics
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Sotex Pharm Firm
Spark Therapeutics
SynerGene Therapeutics
Takara Bio
TAP Biosystems
Thermo Fisher Scientific
TissueGene
ToolGen
UC Berkeley
UC San Francisco
uniQure
US Business Innovation Network
Vertex Pharmaceuticals
Vical Incorporated
ViroMed
VM Biopharma
Voyage Therapeutics
ASCO (American Society of Clinical Oncology)
ASI (Agency for Strategic Initiatives)
CAT (Committee for Advanced Therapies)
CBER (Center for Biologics Evaluation and Research)
CHMP (Committee for Medicinal Products for Human Use)
CHOP (The Children's Hospital of Philadelphia )
DCGI (Drugs Controller General of India )
DHHS (Department of Health and Human Services)
EMA (European Medicines Agency)
FDA (US Food and Drug Administration)
INSERM (Institut National de la Santé et de la Recherche Médicale)
IRB (Institutional Review Boards)
MFDS (Korean Ministry of Food and Drug Safety)
MHLW (Ministry of Health, Labour, and Welfare)
MHRA (Medicines and Healthcare Products Regulatory Agency)
Ministry of Health Commission
NHS (National Health Service)
NICE (the National Institute for Health and Care Excellence)
NIH (National Institutes of Health)
OHRP (Office for Human Research Protections)
PMDA (Pharmaceuticals and Medical Devices Agency)
RCGM (Review Committee of Genetic Manipulation)
Russian Ministry of Healthcare and Social Development
SFDA (State Food and Drug Administration of China )
SMC (Scottish Medicines Consortium)
The Fund for Promotion of Small Innovative Enterprises in Science and Technology
The IGI (Innovative Genomics Initiative)
The Innovative Genomics Initiative
The Walter and Eliza Hall Institute
The Wellcome Trust Sanger Institute
WFH (World Federation of Hemophilia)
WHO (World Health Organization)
Logo: http://mma.prnewswire.com/media/523989/Visiongain_Logo.jpg